Rivermark Medical Kicks Off RAPID III Study for Innovative BPH Treatment

Rivermark Medical Enters New Era of BPH Treatment with FloStent™ System



Rivermark Medical, a trailblazer in urology-focused medical devices, has announced an exciting development in the treatment of benign prostatic hyperplasia (BPH) by enrolling its first patient in the RAPID III clinical study. This pivotal trial aims to assess the safety and effectiveness of the revolutionary FloStent™ System, designed for men suffering from lower urinary tract symptoms due to BPH.

Opening a New Frontier in BPH Management


The RAPID III study is a multicenter, randomized clinical trial that highlights Rivermark's commitment to simplifying treatment solutions for BPH, a condition impacting nearly 40 million men in the United States and over 500 million worldwide. Traditionally, men have faced a range of treatment options—each with associated risks and trade-offs. What sets the FloStent apart is its innovative delivery method, which involves a routine outpatient cystoscopy. This allows for a considerably less invasive procedure when compared to traditional surgical interventions.

On April 23, 2025, the first patient procedure was successfully completed at Freedman Urology, located in Las Vegas, Nevada, by Dr. Sheldon Freedman. As a pioneer in BPH therapies, Dr. Freedman commented, "The FloStent represents a meaningful step forward in providing men with a non-surgical, reversible treatment option for BPH". His excitement underscores the potential this new technology has to enhance patient quality of life without the frequent complications associated with more invasive treatments.

How FloStent™ Works


The FloStent system is designed as a first-line treatment specifically for BPH. It boasts several advantages:

  • - Minimally Invasive: The FloStent can be inserted during a routine procedure, ensuring minimal disruption to patients.
  • - Quick Recovery: Patients can expect a faster recovery timeline, which allows them to resume daily activities swiftly.
  • - Adjustability: Unlike traditional treatments, the FloStent can be retrieved or adjusted post-implantation, ensuring flexibility in ongoing patient care.
  • - No Capital Component: This feature dramatically decreases financial burdens on patients and healthcare facilities, making it a zero-capital therapy.

Dr. Adam Kadlec, co-founder and CEO of Rivermark Medical, emphasized the device's purpose in offering quick symptom relief while reducing the risks often associated with irreversible surgical options. Kadlec stated, "Enrolling the first patient in the RAPID III study marks a major milestone for Rivermark and reflects the growing demand for simple, effective, and accessible BPH therapies."

Understanding the Implications


BPH, while generally not life-threatening, significantly impacts daily life for many men, leading to challenges including frequent urination, urgency, and incontinence. Current treatment options may offer varying degrees of effectiveness but often require patients to make difficult choices regarding efficacy and side effects.

The emergence of FloStent is timely. By enabling physicians to provide this non-surgical solution, Rivermark Medical is playing a crucial role in broadening the horizon of urology, paving the way for clinicians to deliver exceptional patient care without incurring undue risks. As the demand for accessible BPH treatments increases, solutions like FloStent may become foundational in managing this common condition effectively.

For those interested in learning more about the RAPID III clinical trial, additional details can be found at clinicaltrials.gov.

About Rivermark Medical


Rivermark Medical is devoted to redefining the landscape of BPH treatment through innovative and patient-centered therapies that prioritize both outcomes and ease for healthcare providers. To learn more about their offerings, visit rivermarkmedical.com.

Note: FloStent™ is currently an investigational device, with use governed by federal law.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.